The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa

Affiliations

¹ Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Laboratory of Investigative Dermatology, Rockefeller University, New York, USA. Electronic address: jfrew@rockefeller.edu.

Free article

Comment

Kelsey R van Straalen et al. J Invest Dermatol. 2021 Feb.

Free article

. 2021 Feb;141(2):429-431.

doi: 10.1016/j.jid.2020.03.977. Epub 2020 Jun 22.

¹ Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands.
² Laboratory of Investigative Dermatology, Rockefeller University, New York, USA. Electronic address: jfrew@rockefeller.edu.

No abstract available

Comment in

Interactive, Proof of Concept Clinical Trial Design in Hidradenitis Suppurativa.
Gottlieb AB. Gottlieb AB. J Invest Dermatol. 2021 Feb;141(2):431-433. doi: 10.1016/j.jid.2020.06.006. Epub 2020 Jun 22. J Invest Dermatol. 2021. PMID: 32585209 No abstract available.

A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain.
Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G, Hernandez L, Kaffenberger J, Guido G, Lucas K, Montes D, Gold M, Babcock C, Simard J. Gottlieb A, et al. J Invest Dermatol. 2020 Aug;140(8):1538-1545.e2. doi: 10.1016/j.jid.2019.10.024. Epub 2020 Jan 29. J Invest Dermatol. 2020. PMID: 32004568 Clinical Trial.